INTRODUCTION
Combination antiretroviral therapy (cART) has greatly reduced the morbidity and mortality associated with HIV infection, but prevalence of HIV-associated neurocognitive disorders (HAND) remains elevated, even among virally suppressed patients. 1, 2 HAND in these patients is usually only mild to moderate in severity [ie, asymptomatic neurocognitive impairment and mild neurocognitive disorder 1, 3 ] and may not be clinically obvious but can negatively affect everyday functioning, quality of life, and even survival. 4, 5 The greatest burden of the worldwide HIV/AIDS epidemic lies in sub-Saharan Africa (SSA). One of the hardest-hit countries in SSA has been Zambia. In 2007, the last demographic survey in Zambia reported that 14.3% of Zambian adults (16.1% of women and 12.3% of men) were infected with HIV. 6 Most research on HAND has come from Western countries, but in SSA higher prevalences of coinfections may contribute to manifestations of HIV central nervous system (CNS) disease, including neurocognitive impairment. Tuberculosis (TB), the most common serious HIV-related coinfection, is a leading cause of death and disability worldwide. In 2015, one-third of approximately 1.2 million HIV-related deaths were associated with TB. 7 Zambia has one of the highest TB prevalence rates in the world (455/100,000 population), and TB prevalence in HIV-positive (HIV+) persons is 5 times higher than in HIV-negative (HIV2) Zambians. 8 Because systemic inflammation that is associated with central obesity seems to contribute to HAND, we hypothesized that pulmonary TB/HIV coinfection might also damage the brain indirectly, that is, without CNS invasion by Mycobacterium tuberculosis. Cognitive impairment has been associated with the elevated blood levels of the proinflammatory cytokine IL-6 in centrally obese HIV+ patients and HIVuninfected patients with active pulmonary TB. 9, 10 Many other proinflammatory cytokines that increase in pulmonary TB such as INF-alpha or TNF might also contribute to cognitive dysfunction.
Neuropsychological (NP) assessment is an important tool for detecting and categorizing the effects of HIV on the CNS, but until recently, in SSA, a lack of populationappropriate normative standards for NP tests has hampered clinical detection and research into HAND. [11] [12] [13] This situation has now improved, with the recent publication of age-, education-, and gender-corrected NP test norms based on test results of a large sample of healthy, HIV2 adults. 14 Here, we use the published, Zambian NP norms to compare NP functioning of HIV2 controls with that of HIV+ adults without TB (HIV+/TB2) and those with pulmonary TB (HIV+/TB+). The study was conducted in Lusaka, Zambia, where both diseases are common, comorbid conditions. The same NP test battery has been used in multiple other international studies and consistently has been found to be sensitive to effects of HIV infection. 2, [15] [16] [17] We trained and certified local graduate students, who tested participants in English, the language of the Zambian educational system. Some preliminary NP data related to an HIV+ group that included both TB+ and TB2 individuals has been published by Chinyama et al, 18 but without HIV2 controls and not in an international journal.
METHODS

Design
We compared clinical and cognitive data from a crosssectional study of cognition in HIV-infected and HIVuninfected Zambian adults to examine the hypothesis that comorbid pulmonary TB might be associated with greater cognitive impairment in HIV+ patients.
Subjects and Medical Assessments
Participants were drawn from persons attending 6 medical clinics in Lusaka who were identified by the supervising nurse as potential candidates based on their HIV diagnoses. Of 275 HIV+ patients and 324 healthy HIV2 controls, all were 18-65 years old, had at least 5 years of education, and spoke English. All HIV+ participants were urban residents and had been treated with cART for more than 3 months. The mean duration for HIV therapy in the HIV+/TB2 was 2.2 years, whereas in the HIV+/TB+ group, it was 1.6 years.
The participants were divided into HIV2, HIV+/TB2, and HIV+/TB+ groups. Potential participants with extrapulmonary TB (n = 49) were excluded from this study because of uncertainty regarding this diagnosis. This uncertainty was due to limitations in the necessary medical resources such as histopathological analysis of tissue biopsies in Zambia, which is crucial for a correct diagnosis of extrapulmonary TB. 19 Pulmonary TB, as an HIV coinfection, was established through a review of medical records for evidence of diagnosis and treatment for pulmonary TB as determined by either a (1) national TB and leprosy identity card, (2) TB case number, (3) TB treatment ID card, (4) district health office TB listing in a (5) clinic TB register or (6) TB suspect register.
Of the 38 HIV+/TB+ patients, sputum examined by Ziehl-Nielsen stain for acid-fast bacilli had been positive in 53% (20) and negative in 47% (18) . In all smear-negative pulmonary TB cases, chest x-ray was the main supporting diagnostic tool, together with a clinical history consistent with a diagnosis of TB. Cultures and nucleic acid probes for Mycobacterium tuberculosis were not used for diagnosis of Zambian TB suspects during the period of this study. To minimize the effects of symptoms on testing of cognition, all HIV+/TB+ patients were on 4-drug TB treatment regimen for at least 3 months, were responding symptomatically, and were either in intensive or continuous TB treatment phases. The HIV+/TB+ patients were required to be currently free of symptoms suggesting active pulmonary TB, such as prolonged fever, chronic cough, weight loss, malaise, or severe anemia. Neuropsychological functioning was assessed only once. Given that methods to detect multidrug-resistant TB (MDR-TB) in the laboratory were not used in the patients in this study, we cannot rule out that some may have had drugresistant TB. The fact that they were still responding clinically after 3 months of TB therapy, however, suggests that they did not harbor MDR-TB. The prevalence of MDR-TB in Zambia was estimated to be under 1.8% from 2001 to 2008, with no change over these years. 20 CD4 T-cell counts were enumerated by single-platform flow cytometry, either by Facscalibur or Facscount machines, using standard methods. HIV RNA concentrations (viral load) were measured using the AmpliPrep/COBAS TaqMan HIV-1 test. This method combines automated sample preparation for HIV-1 RNA purification, polymerase chain reaction amplification, and detection with the COBAS TaqMan 48 analyzer. Participants were categorized according to whether their HIV viral loads were detectable or undetectable (detection limit at 40 copies/mL). Calibration and quality assessment were conducted according to standard procedures for the instruments.
Healthy Zambian adults of both sexes, and variable age and education (n = 324) were tested to generate normative standards that allowed us to adjust NP test results for effects of sex, age, education, and urban versus rural residency. Details of the procedures and results of the norming study and inclusion of HIV2 participants are reported elsewhere. 2, 14 Exclusion criteria for both HIV+ and HIV2 groups were a history of neurological or psychiatric conditions that could affect cognitive functioning such as epilepsy, closedhead injury with loss of consciousness, coma for any reason, encephalitis or other relevant pre-existing neurologic problems, drug abuse, schizophrenia or bipolar disorder, or physical disability. This information was obtained by means of the UC San Diego HIV Neurobehavioral Research Program's standardized instruments: (1) Neurobehavioral Medical Screening Form that assesses medical and neurological histories and (2) structured substance use form. 15 Also, the NP differences between the HIV+/TB+ and HIV+/TB2 groups remained significant when CD4 counts and HIV viral load were covaried in the analysis. In addition, any potential participants who had clinical indications of CNS disorder were excluded from the study.
To exclude for major depression and for alcohol and drug use disorders, the study used Psychiatric and Drug Abuse Assessment, which involved the Composite International Diagnostic Interview (Version 2.1; World Health Organization), the Beck Depression Scale II, 21 and the Substance Use History form. 15, 22 The Composite International Diagnostic Interview provides DSM-IV/ICD10 diagnosis of present or past major depression and substance use disorder. The Substance Use (CSS) questionnaire contains a list of drugs and alcohol where the participants were required to state which ones and how much they had used. This form records the quantity, frequency, and mode of administration of all substances of abuse that have been used more than 5 times in the person's lifetime. This information is recorded for the last 7 days, for the last 8-30 days, for the remainder of the last year, and for the period of peak lifetime use. Moderate alcohol consumption for men was defined as more than 21 units of alcohol per week and 4 units per day. Moderate alcohol consumption in women was defined as being 14 units of alcohol per week and 3 units per day. More than moderate use during the last 30 days was an exclusion.
All participants provided written informed consent to participate in the study. The Biomedical Research Ethics committee at the University of Zambia (UNZABREC) and the Ministry of Health, Zambia, approved the study.
Neuropsychological Assessment
Students pursuing a Masters of Science in Clinical Neuropsychology at the University of Zambia performed the neuropsychological testing. They were trained and certified for standardized clinical examination of the participants through theoretical and practical courses. Because English is the primary language of instruction in the Zambian education system, all participants spoke English, the language in which the NP testing was performed. Screening for the participants' ability to speak and understand English was performed with the Zambia Achievement Test, a test constructed to quantify academic achievement for the purpose of identifying English mastery in Zambian children in grades 1 through 7. 23 The threshold level of English proficiency for this study was Grade 5 and above. Details for the procedures and results of the norming study and inclusion of HIV2 participants are reported elsewhere. 2, 14 The cognitive domains tested and specific tests were (1) 24 The test battery has been used in many international settings related to NP performance in HIV+ participants, in various languages around the world. 1, 16, [25] [26] [27] [28] [29] [30] The tests have all been adapted and normed, with demographic corrections for age, sex, education, and urban versus rural residence in Zambia. 14 
Statistical Methods
The data were analyzed with SPSS Version 24, using analysis of variances and x 2 tests. Because of multiple comparisons, Bonferroni corrections were performed. The NP tests were combined into 7 functional cognitive domains and summarized as 7 domain T-scores and a (summary) global mean T-score. Some data on the Category and Wisconsin Card Sorting tests were missing for technical reasons. For the 57 subjects who lacked these test results, their executive and global mean T-scores were calculated with the 2 remaining executive function tests. To examine the influence of immunodeficiency on global cognitive functioning, a univariate analysis was performed with the global mean T-score as the continuous dependent variable and the CD4 count and virus detected or not detected in the blood as covariates. Seven domain-deficit scores and a global deficit score (GDS) summarized performance that was in below-expected ("impaired") levels for individuals' demographic characteristics by considering only below-expected performance. The GDS categorizes demographically corrected T-scores on a 5-point scale from normal to severely impaired. A deficit score of 0 is normal performance (T-score $ 40), whereas a deficit score of 1 is mild impairment (T-score = 35-39), 2 is mild-tomoderate impairment (T-score = 30-34), 3 is moderate impairment (T-score = 25-29), 4 is moderate-to-severe impairment (T score = 20-24), and 5 is severe impairment (T-score , 20). Global NP impairment (HAND) was diagnosed if the GDS was equal to or higher than 0.50, and specific domain score of $0.5 suggested impairment in that domain. A GDS cutoff of $0.50 indicates that the individual on average was at least mildly impaired on at least half of the individual test measures in the entire test battery. The use of this one summary score avoids the problem of multiple comparisons when interpreting or comparing results on a test battery and reflects the number and severity of deficits identified by that test battery. All scores in the normal range (one SD below the normative mean or better) are assigned a deficit score of "0." [31] [32] [33] Unlike a mean T-score or other potential summary scores, the GDS also gives more weight to "problems" (impairments) and protects against the possibility of a very good score on one test obscuring a very bad score on another. Blackstone et al indicates that the standard GDS cutoff of $0.50 also virtually guarantees that the participant will meet Frascati criteria for HAND. 3 It has been used effectively in many studies of neuroAIDS in the United States and internationally (including our published work in Zambia).
RESULTS
Demographics and HIV Disease Status
Participants were divided into 3 groups based on their HIV and TB status, HIV2, HIV+/TB2, and HIV+/TB+. (Table 1) . On average HIV2 participants were older than HIV+/TB2 by 2.6 years, and HIV+/TB+ patients by 6.5 years. HIV2 controls also had achieved more years of .7) groups. The proportion of male HIV+ patients (34%) in our sample was less than that of HIV+ persons in the population in Zambia (42%), based on estimated HIV prevalence of 15% in women and 11% of men. 34 The HIV +/TB+ group consisted of 67% males. Again, these sample demographic differences were controlled using the demographically corrected neuropsychological test norms (using demographically corrected T-scores). HIV+/TB+ volunteers had strikingly lower mean CD4 counts than those of HIV +/TB2 patients (324 versus 513 cell/mL), also with all being prescribed cART, they were nevertheless 3-fold more likely to have detectable HIV levels in blood (53% versus 17%).
Mood Status
We administered the Beck Depression Inventory II (BDI-II) to the HIV-infected participants in this study. Their mean score was in the normal to mild area regarding depressed mood. In addition, the TB participants had better BDI-II scores compared with those of the HIV+/TB2. The mean for the HIV+/TB2 group was 10.5 (SD 8.5) versus HIV+/TB+ mean of 7.4 (SD 5.5).
Cognitive Functioning
Both HIV+ groups performed worse than HIV2 controls in 6 of the 7 cognitive domains (all but complex motor skills), and the HIV+/TB+ group was significantly more impaired than the HIV+/TB2 participants on tests that represent the same domains, minus executive functions, which showed a borderline result (Tables 2 and 3 ). Mean GDS in the HIV+/TB+ was 0.69 and higher than the HIV2 (0.25) and HIV+/TB2 (0.39) groups. Using a GDS $0.50 to classify participants as impaired, prevalence rates were 14.2% of the HIV2 controls, 33.8% of the HIV+/TB2, and 55.3% of those with HIV+/TB+ (P , 0.001). These NP differences between the HIV+/TB+ and HIV+/TB2 groups remained significant when CD4 counts and HIV viral load were covaried in the analyses. 
DISCUSSION
In these Zambian volunteers, HIV+ patients with pulmonary TB (HIV+/TB+) were more than 3 times likely to be cognitively impaired than were HIV2 healthy controls (14.2% versus 55.3%) and 1.6 times more likely than HIV +/TB2 patients (33.8% versus 55.3%). The HIV+/TB+ group's mean performance was approximately 1 SD below the performance of the HIV2 controls on many of the cognitive domains examined. HIV+/TB+ patients were the most impaired when compared with HIV+/TB2 in learning (immediate recall), working memory, verbal fluency, memory (delayed recall), and speed of information processing. Executive functions showed a trend in the same direction (P = 0.06), and fine motor control did not differ between these groups.
The results on the Grooved Pegboard test were not in accord with our expectation that the HIV+ participants would evidence at least some impairment in complex motor skills. However, it has been reported that, in the current era of cART, complex motor difficulties are less prevalent in HIVinfected patients than they were in the pre-cART era. 35 Although the HIV+ patients performed better than the HIV2 participants in the current study, we think this probably is a result of chance. In studies in Ethiopia and Uganda performances on the Grooved Pegboard were similar for the HIV+ and HIV2 groups. 12, 36, 37 HIV infection is associated with increased risk for cognitive dysfunction even in patients on effective treatment, but we cannot be sure whether TB acts independently or interacts with HIV to amplify the brain injury assumed to underlie cognitive dysfunction. Additional studies of cognition in HIV+/TB+ and HIV2/TB+ patients are needed to address this question. Likewise, we cannot exclude interactions of TB with other infectious or nutritional (eg, vitamin D) cofactors in our patients. For example, other coinfections with cytomegalovirus and toxoplasma are associated with increased risk for cognitive impairment in HIV+ patients even when they have no clinical evidence of brain disease. 38, 39 The mechanisms for these effects are unclear but can be mediated by (1) immune deficiency (lower current CD4 counts) in HIV+/TB+ patients, (2) elevation of efavirenz levels by rifampicin, a component of TB therapy, or (3) systemic inflammation or immune activation. Low CD4 counts in HIV patients are associated with cognitive impairment. 2 However, in this study, CD4 counts and TB did not interact, and when controlling for these factors, cognitive differences between the 2 HIV-positive groups persisted. In HIV+/TB+ participants, many efavirenz dose-related neurotoxicity contribute to cognitive impairment. 40 It is also known that isoniazide can cause CNS symptoms, during acute or chronic overdoses, 41, 42 but the likelihood that these patients were affected by such overdoses at the times of their study participation is considered to be very small. TB encephalitis and meningitis are uncommon complications of pulmonary TB. If there had been symptoms of CNS infections, the participants would have been referred for brain magnetic resonance imaging. However, TB meningitis may not produce the dramatic symptoms (headache, fever, and delirium) that characterize other more acute forms of bacterial meningitis. Therefore, we cannot rule out that 1 or 2 of our HIV+/TB+ patients might be in early stages of TB meningitis or other CNS opportunistic infections that can diminish cognition. This possibility is, however, unlikely to have affected our findings.
The results from the BDI-II do not suggest that depression contributed to the worse NP performance in the HIV+/TB+ compared with the HIV+/TB2 group because the HIV+/TB+ group had lower average BDI-II scores.
HIV and TB infections each interact with the immune system in multiple overlapping ways. 43, 44 Of potential immune mechanisms for their joint mediation of brain injury, increased systemic inflammation seems the most likely for several reasons. Inflammatory conditions such as central obesity elevate blood levels of inflammatory biomarkers (eg, IL-6) are associated with impaired cognition in both HIV-infected and HIV-uninfected persons. 45, 46 Proinflammatory biomarkers in blood including IL-6 are elevated at the time of diagnosis of pulmonary TB and decreased with effective treatment. 47 Both active and latent TB infections increase the risk of acute myocardial infarction, another disease that is linked to systemic inflammation. 48, 49 Future studies of cognition in HIV2/TB+ patients should include measures of both systemic and CNS inflammation. Other chronic inflammatory coinfections that can affect cognition such as hepatitis C, CMV and latent toxoplasmosis, nutritional deficiencies, and drugs for TB and HIV infections should also be identified and assessed in these patients as potential confounders.
This study contributes to validation of our English language test battery for cognitive assessments in Zambia. We found similar levels of impairment in HIV patients as found by Heaton and colleagues in 5 other studies using a similar battery in a variety of settings and languages (Table  4 ). The prevalence of impairment in HIV+ persons defined as GDS $0.50 ranged from 33% to 45% in 5 other studies using comparable NP test batteries with country-specific, demographically corrected test norms.
The strengths of this study are its use of a comprehensive battery of cognitive tests that have been validated on HIV patients in multiple settings and comparison of the performance of HIV+ patients with normative data from HIV2 controls from the same country. These norms allow correction for normal effects of age, education, sex, and urban versus rural residence. A potential concern is that the HIV+/TB+ group had significantly lower education than both the HIV +/TB2 group and the HIV2 control group from which the NP test norms were developed. This could suggest that the demographically corrected NP norms may not have fully corrected for the low level of education in the HIV+/TB+ group. In this regard, it should be noted that the Zambian NP norms provide corrections for age and education as continuous variables, not by relatively small age · education · sex cells. Also, over half of the HIV2 adults in the norming group had less than 12 years of education (n = 172) and almost a third had education levels less than 10 years (n = 105). Thus, people with lower levels of education were well represented in the Zambian norms. Furthermore, education levels (years completed) were not significantly related to mean T-scores in any of the groups in the current study (including HIV+/TB2 and HIV+/TB+), so the demographic corrections seem to have successfully removed effects of education level. Also, the NP differences between the HIV +/TB+ and HIV+/TB2 groups remained significant when CD4 counts and HIV viral load were covaried in the analyses. The study's limitations include its (1) cross-sectional design, (2) limited data on details regarding antiretroviral and anti-TB treatment, (3) relatively small number of pulmonary TB patients, (4) demographic differences among HIV+ groups that could contribute to their poorer performance on testing (although demographically corrected Zambian test norms should correct for these), (5) inclusion of no HIV negatives with TB, and (6) lack of data on biomarkers of inflammation in blood.
We conclude that the prevalence of impairment in controls and HIV+ patients was consistent with those found in 5 other international settings using similar assessments. Both HIV and TB seem to contribute to cognitive impairment in our Zambian sample. Patients with pulmonary TB and HIV coinfections have a higher prevalence of NCI than do HIV patients without pulmonary TB. NCI could decrease adherence to HIV and TB medications and thus reduce the effectiveness of both treatments in these patients. The higher prevalence of NCI in HIV+/TB+ patients may indicate a need to assist with adherence to medications for treating both conditions and thereby reducing brain impairment. Differences in levels of immune deficiency or systemic inflammation may help to explain differences in the impact of HIV and TB coinfections and should be pursued in future studies.
